All In Biotech

Drug Trial Radar · NCT07557355

A Study of SRSD384 in Overweight or Obese Participants

A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD384 in Overweight or Obese Participants

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Sirius Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).

Conditions

  • Overweight , Obesity

Interventions

  • SRSD384 injectionDrug

    Administered S.C. per the protocol

  • PlaceboDrug

    Administered S.C. per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: 168 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NovaTrials

    Charlestown, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.